Showing 2701-2710 of 2985 results for "".
- Regeneron and Sanofi Announce Positive Results from Phase IIb Study of Dupilumab for Atopic Dermatitishttps://practicaldermatology.com/news/20140715-regeneron_and_sanofi_announce_positive_results_from_phase_iib_study_of_dupilumab_for_atopic_dermatitis/2459168/Regeneron Pharmaceuticals, Inc. and Sanofi announced positive results from a Phase IIb dose-ranging study of dupilumab for moderate to severe atopic dermatitis. All doses of dupilumab met the primary endpoint of a greater improvement in Eczema Area and Severity Index (EASI) scor
- PuraCap Pharmaceutical Introduces EpiCeram 225g Airless Pumphttps://practicaldermatology.com/news/20140711-puracap_pharmaceutical_introduces_epiceram_225g_airless_pump/2459174/PuraCap Pharmaceutical introduced the newest addition to the EpiCeram product line, the EpiCeram 225g Airless Pump. The airless pump gives patients more EpiCeram to treat any size area of atopi
- Merz Signs Licensing Agreement with Brickell Biotech for Development of a Novel Retinoid Therapyhttps://practicaldermatology.com/news/20140702-merz_signs_licensing_agreement_with_brickell_biotech_for_development_of_a_novel_retinoid_therapy/2459182/Merz North America, Inc. signed an agreement with Brickell Biotech, Inc. granting Merz an exclusive North American license with certain additional international rights to develop and commercialize, a completely novel retinoid compound for the treatment of skin conditions respons
- Merz to Acquire Ulthera, Inc.https://practicaldermatology.com/news/20140630-merz_to_acquire_ulthera_inc/2459184/Merz and Ulthera have entered a definitive merger agreement pursuant to which Merz will acquire Ulthera, Inc, a global medical device company focused on developing and commercializing technologies for aesthetic and medical applications using its therapeutic ultrasound platform technology. Valued
- New National Psoriasis Foundation Program Prioritizes Psoriatic Arthritishttps://practicaldermatology.com/news/20140626-new_national_psoriasis_foundation_program_prioritizes_psoriatic_arthritis/2459186/According to the National Psoriasis Foundation (NPF), millions of Americans with psoriatic arthritis struggle to get the health care and treatments they need to manage their condition. To help change that, the NPF launched the largest realignment and expansion of its psoriatic a
- The Skin Type Solutions® Franchise System Launched by Leslie Baumann, MDhttps://practicaldermatology.com/news/20140625-the_skin_type_solutionsfranchise_system_launched_by_leslie_baumann_md/2459189/The Skin Type Solutions® Franchise model, just introduced by dermatologist Leslie Baumann, MD, is intended to allow every dermatologist to be the primary source of skincare guidance before a patient makes a purchase, and make the proper skincare regimens available right there at the office. Th
- AMBI® Skincare Names Model Search Winnerhttps://practicaldermatology.com/news/20140623-ambi_skincare_names_model_search_winner/2459194/Charnee Long, 21, is the Grand Prize Winner of the first-ever nationwide AMBI® Model Search. Charnee was one of 10 finalists selected from a pool of more than 6,099 entrants. She will be featured in a national print campaign, receiving a three day/two night trip to New York City for a pro
- Sente, Inc. Awarded European Patent for Active Ingredient in Proprietary Dermal Repair Creamhttps://practicaldermatology.com/news/20140619-sente_inc_awarded_european_patent_for_active_ingredient_in_proprietary_dermal_repair_cream/2459199/Sente has been granted the European Patent for use of a low molecular weight heparan sulfate (HS) for cosmetic products. HS is the most biologically active glycoprotein that is present in all layers of human skin and is the scientific base to Sente Inc's proprietary Dermal Repair Cream. M
- Allergan Reiterates its Belief that Valeant's Business Model is Unsustainablehttps://practicaldermatology.com/news/20140616-allergan_reiterates_its_belief_that_valeants_business_model_is_unsustainable/2459204/Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today reiterated the Company's concern regarding Valeant Pharmaceuticals International, Inc.'s ("Valeant") unsustainable business model, which relies on serial acquisitions and cost reductions, as opposed to top-line revenue growth and operati
- Valeant Pharmaceuticals Receives FDA Clearance For Restylane Silkhttps://practicaldermatology.com/news/20140616-valeant_pharmaceuticals_receives_fda_clearance_for_restylane_silk/2459205/The FDA issued marketing clearance for Valeant Pharmaceuticals International, Inc.'s Restylane Silk Injectable Gel with 0.3% Lidocaine for submucosal implantation for lip augmentation and dermal implantation for correction of perio